What would you recommend as adjuvant treatment for a patient with Stage III melanoma?
If staged so due to satellite lesion and negative nodes? How do you decide between adjuvant PD-1 inhibitor or BRAF/MEK inhibition in BRAF-mutated patients?
1 Answer
Mednet Member
Medical Oncology · University of Colorado
Answered on
Good question at just the right time. As of last week the treatment of stage III melanoma has dramatically changed based on 2 trials reported in the NEJM. The first trial in 906 patients demonstrating that nivolumab is superior to iplimumab with much less toxicity, was stopped early because of clear...
Join for free or sign in to see the full answer